Clovis Oncology
FDA Grants New Indication for Rubraca
The FDA granted a new indication for Rubraca for the maintenance treatment of recurrent ovarian, fallopian tube or ...
APRIL 6, 2018
FDA Approves Rubraca for Advanced Ovarian Cancer
This is the first and only PARP inhibitor in the U.S. indicated to treat advanced ovarian cancer patients who have ...
DECEMBER 19, 2016
Load more